Research results have shown that the obesity treatment ‘Wegobee’ (semaglutide) reduced weight but lost relatively less muscle, and partially improved muscle strength and metabolic function.
According to the industry on the 26th, the SEMALEAN study, published in the international journal ‘Diabetes, Obesity and Metabolism’ in the field of endocrinology, administered 2.4 mg of Wigobi to 106 severely obese patients with an average body mass index (BMI) of 46.㎏/㎡ and followed them for 12 months.
As a result, the patients’ weight decreased by an average of 12.7% over one year. Of these, more than 80% of the loss was due to fat loss, and muscle mass loss was only about 3kg, or about 18% of the total weight loss.